Upstream Bio (NASDAQ:UPB) Lowered to “Sell” Rating by Wall Street Zen

Upstream Bio (NASDAQ:UPB) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Other equities research analysts have also issued research reports about the company. Lifesci Capital assumed coverage on Upstream Bio in a research report on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 price objective on the stock. Evercore downgraded Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 target price for the company. in a research report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, January 21st. Finally, Mizuho raised Upstream Bio to a “strong-buy” rating in a research note on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Upstream Bio presently has an average rating of “Moderate Buy” and a consensus target price of $39.00.

Upstream Bio Price Performance

Shares of Upstream Bio stock opened at $8.67 on Friday. The company’s 50 day moving average price is $15.93 and its two-hundred day moving average price is $21.35. The firm has a market capitalization of $468.53 million, a P/E ratio of -3.25 and a beta of 2.96. Upstream Bio has a fifty-two week low of $5.14 and a fifty-two week high of $33.68.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.06). Upstream Bio had a negative return on equity of 34.90% and a negative net margin of 5,026.03%.The company had revenue of $0.67 million for the quarter, compared to analyst estimates of $0.52 million. On average, analysts expect that Upstream Bio will post -4.3 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. bought a new stake in shares of Upstream Bio in the 4th quarter valued at about $29,000. Torren Management LLC bought a new position in shares of Upstream Bio during the fourth quarter worth about $30,000. Empowered Funds LLC bought a new position in shares of Upstream Bio during the fourth quarter worth about $45,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Upstream Bio in the fourth quarter worth approximately $71,000. Finally, Russell Investments Group Ltd. boosted its holdings in Upstream Bio by 1,963.9% in the third quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company’s stock valued at $57,000 after acquiring an additional 2,887 shares during the last quarter.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.